consolidation

The subject of biotech company consolidations has been talked about more of recent times & while there have been the odd instances of that it has been suggested that it is likely & preferable that more occur as the Australian market is considered too fragmented.
So, like everyone else on this board, I've been pondering the reason for this TH & have started getting this gut feeling that we may be looking at an amalgamation, hopefully with another aussie biotech.
Should it be the worst option, a T/O by an overseas company, then at least we could expect a sizeable offer above current market price, which would normally be around 40% but should be considerably above that with the impending earnings from fondaparinux sales. All JMHO!